These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 35078683)

  • 1. Incidence, clinical characteristics, and diagnostic approach in transthyretin amyloid cardiomyopathy: The Kumamoto Cardiac Amyloidosis Survey.
    Takashio S; Tokitsu T; Matsukawa M; Sakaino N; Fujimoto K; Sakamoto T; Noda K; Tsunoda R; Misumi I; Hirai N; Doi H; Koide S; Mizuno Y; Hirose T; Kurokawa H; Kajiwara I; Ohba K; Miyamoto S; Araki S; Yamamoto E; Matsushita K; Ueda M; Tsujita K;
    J Cardiol; 2022 Jul; 80(1):49-55. PubMed ID: 35078683
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence, characteristics and outcomes of older patients with hereditary versus wild-type transthyretin amyloid cardiomyopathy.
    Porcari A; Razvi Y; Masi A; Patel R; Ioannou A; Rauf MU; Hutt DF; Rowczenio D; Gilbertson J; Martinez-Naharro A; Venneri L; Whelan C; Lachmann H; Wechalekar A; Quarta CC; Merlo M; Sinagra G; Hawkins PN; Fontana M; Gillmore JD
    Eur J Heart Fail; 2023 Apr; 25(4):515-524. PubMed ID: 36644836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Frequency of hereditary transthyretin amyloidosis among elderly patients with transthyretin cardiomyopathy.
    Maestro-Benedicto A; Vela P; de Frutos F; Mora N; Pomares A; Gonzalez-Vioque E; Briceño A; Cabrera E; Cobo-Marcos M; Dominguez F; Gonzalez-Lopez E; Segovia J; Lara-Pezzi E; Garcia-Pavia P
    Eur J Heart Fail; 2022 Dec; 24(12):2367-2373. PubMed ID: 35999650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transthyretin Amyloid Cardiomyopathy-Current and Future Therapies.
    Yadav JD; Othee H; Chan KA; Man DC; Belliveau PP; Towle J
    Ann Pharmacother; 2021 Dec; 55(12):1502-1514. PubMed ID: 33685242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evolving epidemiology of transthyretin amyloid cardiomyopathy due to increased recognition in women.
    Prasad M; Kim M; Chandrashekar P; Zhao Y; Fischer KL; Nazer B; Masri A
    Int J Cardiol; 2023 Mar; 374():116-119. PubMed ID: 36587655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic Pitfall and Clinical Characteristics of Variant Versus Wild-Type Transthyretin Amyloid Cardiomyopathy in Asian Population: The Korean Nationwide Cohort Study.
    Kim D; Youn JC; Lee HW; Oh J; Son JW; Cho HJ; Lee S; Shah NR; Kittleson MM; Jeon ES
    J Korean Med Sci; 2024 May; 39(19):e163. PubMed ID: 38769922
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Carpal tunnel syndrome and spinal canal stenosis: harbingers of transthyretin amyloid cardiomyopathy?
    Aus dem Siepen F; Hein S; Prestel S; Baumgärtner C; Schönland S; Hegenbart U; Röcken C; Katus HA; Kristen AV
    Clin Res Cardiol; 2019 Dec; 108(12):1324-1330. PubMed ID: 30953182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Healthcare resource use of patients with transthyretin amyloid cardiomyopathy.
    Lauppe R; Liseth Hansen J; Fornwall A; Johansson K; Rozenbaum MH; Strand AM; Vakevainen M; Kuusisto J; Gude E; Smith JG; Gustafsson F
    ESC Heart Fail; 2022 Jun; 9(3):1636-1642. PubMed ID: 35365974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First Norwegian case of hereditary ATTR amyloidosis with a novel transthyretin variant.
    Lyng CS; Gude E; Hodt A; Knudsen EC
    Scand Cardiovasc J; 2023 Dec; 57(1):2174269. PubMed ID: 36734834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Causes of Cardiovascular Hospitalization and Death in Patients With Transthyretin Amyloid Cardiomyopathy (from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial [ATTR-ACT]).
    Miller AB; Januzzi JL; O'Neill BJ; Gundapaneni B; Patterson TA; Sultan MB; López-Sendón J
    Am J Cardiol; 2021 Jun; 148():146-150. PubMed ID: 33667442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Penetrance of the Transthyretin V122I Variant in Older Black Patients With Heart Failure: The SCAN-MP (Screening for Cardiac Amyloidosis With Nuclear Imaging in Minority Populations) Study.
    Madhani A; Sabogal N; Massillon D; Paul LD; Rodriguez C; Fine D; Helmke S; Winburn M; Kurian D; Raiszadeh F; Teruya S; Cohn E; Einstein AJ; Miller EJ; Connors LH; Maurer MS; Ruberg FL
    J Am Heart Assoc; 2023 Aug; 12(15):e028973. PubMed ID: 37486082
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sporadic Cardiac Amyloidosis by Amyloidogenic Transthyretin V122I Variant.
    Nehashi T; Oikawa M; Amami K; Kanno Y; Yokokawa T; Misaka T; Yamada S; Kunii H; Nakazato K; Ishida T; Takeishi Y
    Int Heart J; 2019 Nov; 60(6):1441-1443. PubMed ID: 31666456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments.
    Sekijima Y
    J Neurol Neurosurg Psychiatry; 2015 Sep; 86(9):1036-43. PubMed ID: 25604431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic testing improves identification of transthyretin amyloid (ATTR) subtype in cardiac amyloidosis.
    Brown EE; Lee YZJ; Halushka MK; Steenbergen C; Johnson NM; Almansa J; Tedford RJ; Cingolani O; Russell SD; Sharma K; Judge DP
    Amyloid; 2017 Jun; 24(2):92-95. PubMed ID: 28494620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Steep increase in the number of transthyretin-positive cardiac biopsy cases in Japan: evidence obtained by the nation-wide pathology consultation for the typing diagnosis of amyloidosis.
    Naiki H; Yamaguchi A; Sekijima Y; Ueda M; Ohashi K; Hatakeyama K; Ikeda Y; Hoshii Y; Shintani-Domoto Y; Miyagawa-Hayashino A; Tsujikawa H; Endo J; Arai T; Ando Y
    Amyloid; 2023 Sep; 30(3):321-326. PubMed ID: 36795075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transthyretin amyloidosis cardiomyopathy in Greece: Clinical insights from the National Referral Center.
    Bampatsias D; Theodorakakou F; Briasoulis A; Georgiopoulos G; Dimoula A; Papantoniou V; Papantoniou I; Skiadaresi C; Valsamaki P; Repasos E; Petropoulos I; Delialis D; Papathoma A; Koutsis G; Tselegkidi ME; Stamatelopoulos K; Kastritis E
    Hellenic J Cardiol; 2024; 79():25-34. PubMed ID: 37805173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Review of Novel Agents and Clinical Considerations in Patients With ATTR Cardiac Amyloidosis.
    Benbrahim M; Norman K; Sanchorawala V; Siddiqi OK; Hughes D
    J Cardiovasc Pharmacol; 2021 May; 77(5):544-548. PubMed ID: 33657048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ATTR Epidemiology, Genetics, and Prognostic Factors.
    Obi CA; Mostertz WC; Griffin JM; Judge DP
    Methodist Debakey Cardiovasc J; 2022; 18(2):17-26. PubMed ID: 35414855
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of Transthyretin Cardiac Amyloidosis Using Serum Retinol-Binding Protein 4 and a Clinical Prediction Model.
    Arvanitis M; Koch CM; Chan GG; Torres-Arancivia C; LaValley MP; Jacobson DR; Berk JL; Connors LH; Ruberg FL
    JAMA Cardiol; 2017 Mar; 2(3):305-313. PubMed ID: 28196196
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Case of Early Hereditary Transthyretin Amyloid Cardiomyopathy Recognition With Genetic Screening: A Case Report.
    Juarez M; Del Rio-Pertuz G; Parmar K; Bois MC; Shurmur S; Argueta-Sosa E
    J Prim Care Community Health; 2022; 13():21501319211062682. PubMed ID: 34983267
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 19.